Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5929017 | 0.87 | — | — | |
| SCHEMBL5929061 | 0.75 | POLB (0.39) | GAAKMT2AKDM4EALDH1A1HTT | |
| SCHEMBL5929363 | 0.71 | KMT2A (0.39) | GAAKMT2AKDM4EALDH1A1 | |
| SCHEMBL5929030 | 0.69 | KDM4E (0.36) | GAAKMT2AKDM4EALDH1A1HTT | |
| SCHEMBL5929210 | 0.69 | KDM4E (0.35) | GAAKMT2AKDM4EALDH1A1CRHBP | |
| SCHEMBL5929118 | 0.68 | KMT2A (0.36) | GAAKMT2AKDM4EALDH1A1CRHBP | |
| SCHEMBL5929042 | 0.68 | CFB (0.38) | GAAKMT2AKDM4EALDH1A1 | |
| SCHEMBL5929141 | 0.68 | KMT2A (0.38) | GAAKMT2AKDM4EALDH1A1HTT | |
| SCHEMBL5929034 | 0.67 | CFB (0.37) | GAAKMT2AKDM4EALDH1A1HTT | |
| SCHEMBL5928958 | 0.67 | LMNA (0.43) | GAAKMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060154917-A1 | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators | NEUROGEN CORPORATION (US) | 2006-07-13 | — | — | US | disclosed |
| WO-2005007087-A2 | SUBSTITUTED (HETEROCYCLOALKYL)METHYL AZOLE DERIVATIVES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154917-A1 | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators | C5AR1, C5AR2, C3AR1 | GAA 4885/4885KMT2A 2955/4885KDM4E 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.